In mouse bone marrow primary cultures, the formation of osteoclast-like, i.e. tartrate-resistant acid phosphatase (TRAP)-and calcitonin receptor-positive multinucleated cells (MNC), when induced by 1␣,25-dihydroxyvitamin D 3 (1␣,25(OH) 2 D 3 ), can be suppressed by 17␤-estradiol (17␤-E 2 ), whereas 17␣-E 2 is without any effect. 17␤-E 2 , above 10 Ϫ11 M, significantly reduced 1␣,25(OH) 2 D 3 -mediated TRAP ϩ MNC formation in cultured bone marrow cells from both female and male mice. The estrogen at 10 Ϫ8 M suppressed the peak response to the vitamin D sterol by 50%. 17␤-E 2 significantly suppressed basal and 1␣,25(OH) 2 D 3 -stimulated cellular production of interleukin (IL)-6. IL-6 alone, although bone marrow cells in hormone-free culture produced appreciable amounts of the cytokine, did not induce any TRAP ϩ MNC. Therefore, the changes in IL-6 production induced by the hormones could not be the sole determinant for the extent of TRAP ϩ MNC formation. However, the stimulatory effect of 1␣,25(OH) 2 D 3 on osteoclastogenesis nevertheless can be significantly reduced by a neutralizing monoclonal anti-IL-6 antibody. In the presence of 10 Ϫ8 M 17␤-E 2 , the anti-IL-6 monoclonal antibody does not achieve any further suppression of 1␣,25(OH) 2 D 3 -related osteoclastlike cell formation. Our data suggest that induction of osteoclastogenesis by 1␣,25(OH) 2 D 3 is partially dependent on IL-6 signaling and can be modulated by 17␤-E 2 through interference with IL-6 receptor activation, in addition to inhibition of IL-6 production by marrow stromal cells. (Endocrinology 138: [4567][4568][4569][4570][4571] 1997) A LTHOUGH the development of so-called postmenopausal osteoporosis has been convincingly linked to increased osteoclast activity resulting from estrogen withdrawal caused by ovarial insufficiency, and conversely, estrogens are being successfully used for inhibition of osteoclastic bone resorption in treatment of osteoporosis, the cellular mechanisms underlying the positive effect of estrogen on bone mineral density and structure have not yet been elucidated. Estrogen has been shown to have a direct inhibitory effect on activated osteoclasts but could also act on osteoblasts and bone marrow cells to modulate the release of paracrine factors that then interfere with osteoclast formation from undifferentiated hematopoietic precursors (for review see, for example, Refs. 1 and 2); thus, estrogen increases the release of transforming growth factor-␤, a potent inhibitor of bone resorption, from cultured human osteoblasts and possibly inhibits the release of two major bone-resorbing cytokines, interleukin (IL)-1 and IL-6, from peripheral blood mononuclear cells or bone marrow stromal cell lines, respectively. The observation of Jilka et al. (3), that administration of estrogen to ovariectomized mice reduced the potential of bone marrow cells to form osteoclasts in vitro, prompted us to search for a direct effect of estrogen on osteoclast development in naive bone marrow cultures, although, so far, no in vitro study had been published to suggest that estrogens could directly attenuate the generation of osteoclasts from marrow cells. The present study, therefore, is the first experimental account that 17␤-estradiol (17␤-E 2 ), in fact, is able to specifically interfere with differentiation of hematopoietic precursors into osteoclast-like cells in 1␣,25-dihydroxyvitamin D 3 (1␣, 25(OH) 2 D 3 )-treated primary bone marrow cultures. Furthermore, we provide evidence that the inhibitory effect of 17␤-E 2 , which cannot be mimicked by its receptorinactive conformer 17␣-E 2 , results not only from inhibition of IL-6 production by marrow cells but also from blocking of IL-6 signaling, which partially mediates the effect of 1␣,25(OH) 2 D 3 on osteoclast-like cell formation.
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with a sterile 26-gauge needle and flushed with 5 ml DMEM (supplemented with 1% FCS, 2.0 mm glutamine, and 1% penicillin/streptomycin). Marrow cells were washed and then suspended in ␣-MEM (Glutamax I, without phenol red) containing 10% FCS, 1 mm HEPES, and 1% penicillin/streptomycin) at 4 ϫ 10 6 cells/ml. Then, 0.5-ml aliquots were plated in 24-well dishes. Hormones were added on day 1 of culture. Two hundred fifty microliters of medium were replaced by fresh additions every other day. Cultures were performed for 8 days.
Histochemical determination of tartrate-resistant acid phosphatase (TRAP)
Multinucleated cells (MNC) were checked for the presence of the osteoclast marker enzyme TRAP. For this purpose, cells were fixed in formaline/acetone/citric acid and reacted for enzyme activity using a commercially available kit (Sigma, Deisenhofen, Germany). Positive cells appeared as dark red. In each of at least three separate experiments, TRAP ϩ MNC were counted in eight wells per treatment group.
Calcitonin (CT) receptor assay
Cells were grown on Thermanox (Nunc, Naperville, IL) coverslips. CT-receptor-positive cells were detected after incubation with [
125 I]-labeled salmon CT (sCT; 0.2 nm) for 2 h in the absence or presence of cold sCT (10 Ϫ7 m). After two washings with PBS, cells were fixed and stained for TRAP (as described before), dipped in LM-1 photographic emulsion (Amersham, Arlington Height, IL), and developed after a period of 10 days at 4 C, according to the instructions of the manufacturer.
IL-6 bioassay
IL-6 activity was determined in the culture medium using the IL-6-dependent B9 murine hybridoma cell line, as described by Holt et al. (5) with only minor modifications. B9 cells were supplied by Dr. Walter Reinisch, Department of Gastroenterology, University of Vienna Medical School, and were grown in RPMI 1640 medium (Sigma) containing 2 mm glutamine, 10% FCS, 25 mm HEPES, 100 U/ml benzylpenicillin, 100 g streptomycin, and 50 m 2-mercaptoethanol (Merck, Darmstadt, Germany). Before the assay, B9 cells were washed with PBS and then diluted in the medium so that 100-l aliquots, containing 5000 cells, could be added to each well of a microtiter plate. Then, 100-l aliquots of standard solutions, containing 0.1-100 pg/ml of recombinant mouse (rm) IL-6 or of serial dilutions of marrow culture medium, were added and cells grown at 37 C in a humidified atmosphere with 5% CO 2 for 3 days. After this time, 125 l of 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma), at 5 mg/ml in PBS, were added to each well. After 4 h incubation at 37 C, the formazan precipitate formed through the dehydrogenase activity of the B9 cells was dissolved by addition of 25 l/well of 0.04 m HCl in isopropanol. Absorbance of samples was determined at 570 nm. The working range of the assay was between 1-30 pg/ml IL-6.
To test the neutralizing capacity and specificity for bioactive IL-6 of the rat antimouse monoclonal IgG 1 , antibody used in the present study to inhibit IL-6-dependent TRAP ϩ MNC formation, rmIL-6, in the range between 0 -100 pg/ml, was preincubated, for 1 h before the bioassay, with the monoclonal IL-6 antibody or with rat IgG 1 as control, both at 1 g/ml. Although the nonimmune IgG had no effect, bioactivity of IL-6 was reduced by the monoclonal anti-IL-6 antibody, by at least 95%, at any concentration of the cytokine.
Reagents
Culture media and supplements were obtained from GIBCO-BRL (Life Technologies, Gaithersburg, MD). FCS was from Sebak (Aidenbach, Germany). Before the study, we tested several batches of FCS for their ability to induce TRAP ϩ MNC, because Hattersley and Chambers (6) observed the appearance of those cells also in untreated control cultures. We found high variations in the ability to induce polykaryon formation among different batches of FCS but were able to find some that did not induce any TRAP ϩ MNC at all, and that, therefore, were selected for further experimentation. When analyzed for the hormones used in the present study by radioligand assay (courtesy Dr. C. Bieglmayer, Endocrine Analytical Laboratory, Department of Clinical Chemistry, University of Vienna), FCS was found to contain 1.0 ϫ 10 Ϫ10 m 1␣,25(OH) 2 D 3 , and less than 10 Ϫ12 m 17␤-E 2 . In addition, it also contained an average IL-6 bioactivity of 30 pg/ml. 1␣,25(OH) 2 D 3 was a generous gift from Hoffmann-LaRoche (Basle, Switzerland). 17␤-E 2 and sCT were purchased from Sigma. rmIL-6 and a rat antimouse IL-6 monoclonal IgG 1 antibody were obtained from Genzyme (Cambridge, MA), rat IgG 1 isotype from Pharmingen (San Diego, CA), and [
125 I]-labeled sCT from Amersham.
Data reproducibility and statistical analysis
All experimental protocols were repeated at least three times with similar results. Statistic analysis were performed by ANOVA and twotailed unpaired Student's t test. Results were considered significant at the 5% confidence level.
Results

Formation of osteoclast-like cells in bone marrow cultures: validation of the method
The effect of 1␣,25(OH) 2 D 3 on induction of TRAP-positive multinucleated cells (MNC) was studied as described by Rubin et al. (4) . Figure 1 shows that in control cultures, though they contained 1␣,25(OH) 2 D 3 at a residual concentration of 10 Ϫ11 m (see Materials and Methods), formation of TRAP-positive MNC was nil. Only when the steroid hormone concentration was raised by 2 orders of magnitude, did TRAP-positive MNC appear in significant numbers. The peak response to 1␣,25(OH) 2 D 3 , yielding an average of 320 TRAP-positive MNC per well, was observed at a sterol concentration of 10 Ϫ8 m. Hattersley and Chambers (6) provided evidence that TRAP-positivity and multinuclearity alone are not satisfying criteria for the characterization of cells as osteoclast-like. It was crucial, therefore, to demonstrate the expression of CT receptors on the TRAP-positive MNC formed in our culture system (7) (8) (9) (10) (11) . In fact, more than 98% of TRAP ϩ MNC generated in the presence of 1␣,25(OH) 2 simultaneous specific 125 I-CT binding (Fig. 2) and must, therefore, be considered osteoclast-like.
Estrogen inhibition of osteoclast-like cell formation
We then investigated the effect of estrogen on osteoclast development. In the absence of 1␣,25(OH) 2 Ϫ10 m (Fig. 3) . It must be noted that the hormonally inactive conformer 17␣-E 2 had no effect, whatsoever, on vitamin D-induced osteoclast-like cell formation (Fig. 3) .
IL-6 production by bone marrow cells: effects of 1␣,25(OH) 2 D 3 and 17␤-E 2
Although increased IL-6 release from marrow stromal cells has been considered the main reason for enhanced osteoclastic bone resorption observed in estrogen deficiency, direct evidence for a suppressive effect of estrogen on IL-6 production in native bone marrow cultures has never been obtained.
Data collated in Table 1 clearly indicate that bone marrow cells in culture constitutively produce considerable amounts of the cytokine. IL-6 production can be significantly augmented by 1␣,25(OH) 2 D 3 . In contrast, 17␤-E 2 suppresses basal and 1␣,25(OH) 2 D 3 -induced IL-6 release from cultured bone marrow cells. Because none of the hormone treatments had an effect on cellular protein (data not shown), the observed changes in IL-6 release cannot be caused by variations in cell numbers but most likely reflect hormonal effects on cytokine production rates.
It must be mentioned that, though untreated cultures contained relatively high amounts of IL-6, osteoclast-like cell formation could not be observed. Hence, the changes in IL-6 levels induced by the hormones under investigation could thus not account for their respective effects on TRAP ϩ MNC numbers.
Effect of an anti-IL-6 monoclonal antibody (mAb) on 1,25(OH) 2 D 3 -induced TRAP
ϩ MNC formation Nevertheless, a role for endogenous IL-6 in the induction of osteoclastogenesis by 1␣,25(OH) 2 D 3 could be envisaged from experiments in which we added a monoclonal rat antimouse IL-6 antibody to mouse bone marrow cultures treated with 1␣,25(OH) 2 D 3 , alone or in combination with 17␤-E 2 . The anti-IL-6 mAb alone, when added at 1 g/ml, i.e. at a concentration a hundredfold of that necessary to neutralize any IL-6 in the culture medium, achieved a partial, but significant (P Յ 0.01), inhibition of osteoclast-like cell formation induced by 10 Ϫ8 m 1␣,25(OH) 2 D 3 (Fig. 4) . The extent of the inhibitory effect of the anti-IL6 mAb was not significantly different from that of 10 Ϫ8 m 17␤-E 2 and was also not changed when both the anti-IL-6 mAb and the estrogen were present in the culture medium (Fig. 4) . Data are means Ϯ SEM (n ϭ 8) from two separate experiments and were obtained by correction for contribution of IL-6 contained in 10% FCS (see Materials and Methods) to total IL-6 bioactivity, as measured in marrow culture media.
a Statistically significant difference from untreated control (at least at P Ͻ 0.05).
Discussion
Until now, the evidence that estrogen suppresses osteoclast-like cell formation from bone marrow cells, though convincing, was rather indirect: Manolagas' group had shown that estrogen loss in mice caused by ovariectomy enhanced IL-6 mediated osteoclast development in ex vivo bone marrow cultures (3). The present study now demonstrates, for the first time, a direct effect of exogenous estrogen on formation of osteoclast-like cells in primary bone marrow cultures. We are thus able to characterize some details of the mechanism of inhibitory action of estrogen on induction of osteoclast-like cell formation by 1␣,25(OH) 2 D 3 , which, in contrast to results from ex vivo studies (12) , was observed in bone marrow cells derived from both female and male mice.
We are fully aware of the fact that, despite the intense and longstanding interest in estrogen effects on bone, only Kaji et al. (13) just recently reported on a direct inhibitory effect of 17␤-E 2 on osteoclast-like cell formation in unfractionated bone cell cultures or hematopoietic blast cells. However, the estrogen inhibited formation of TRAP ϩ MNC only when induced by PTH and had no effect on 1␣,25(OH) 2 D 3 -stimulated osteoclast formation. Also, Kitazawa et al. (14) failed to demonstrate an effect of 17␤-E 2 on osteoclast-like cell formation in marrow cultures containing 10 Ϫ8 m 1␣,25(OH) 2 D 3 . We want to emphasize that the inhibitory effect of estrogen on osteoclastogenesis is not specific for the HIM:OF1 strain used in the present study, because it occurred to the same extent in marrow cell cultures derived from Balb-c mice, which we had used initially (15) . Thus, marrow cell cultures derived from the strains used in the aforementioned studies, namely BDF 1 and C3H/Hen, respectively, might differ from HIM:OF1 or Balb-c, with respect to the expression of one or more factors that could be critical for the establishment of estrogen responsiveness, such as estrogen receptor (ER) level, IL-6 production, IL-6 receptor, or gp130 expression, as discussed below.
The inhibitory effect of 17␤-E 2 on 1␣,25(OH) 2 D 3 -stimulated osteoclast-like cell formation, observed in the present study, was certainly specific, inasmuch as it could not be reproduced by its nonestrogenic stereoisomer, 17␣-E 2 . Furthermore, partial inhibition of osteoclast development by 17␤-E 2 showed a clear concentration dependency in the nanomolar range (Fig. 3) . Together, this suggests that binding to the cytoplasmic high-affinity ER is required to elicit the observed action of 17␤-E 2 on bone marrow cells. There is evidence from several laboratories, including ours, that the ER is expressed in stromal bone marrow cells (15, 16) .
It should be noted that 17␤-E 2 , even at its most effective concentration of 10 Ϫ8 m, did only partially inhibit the effect of 1␣,25(OH) 2 D 3 on TRAP ϩ MNC formation (Fig. 3) . Therefore, one can assume that the calcemic hormone induces osteoclast differentiation, to a substantial extent, also in an estrogen-insensitive fashion.
Girasole et al. (17) reported on an inhibitory action of 17␤-E 2 on IL-6 production by marrow-derived stromal cells. This has been shown to be caused by transcriptional regulation of IL-6 gene expression by the ER (18) . The present study provides evidence that IL-6 production by bone marrow cells is under multihormonal control. Also, we have shown previously that stromal cells in primary culture are positive for the ER and the vitamin D receptor (10) . We therefore suggest that 1␣,25(OH) 2 D 3 and 17␤-E 2 affect IL-6 release from stromal cells through receptor-mediated regulation of IL-6 gene activity. An important question concerns the possible involvement of IL-6 in generation of osteoclast-like cells from undifferentiated monocytic precursors (1, 19) . In view of the fact that untreated cultured bone marrow stromal cells release appreciable amounts of IL-6 into the medium and IL-6 alone (i.e. in the absence of 1␣,25(OH) 2 D 3 , cannot induce TRAP ϩ MNCs), it is obvious that modulation of IL-6 production by either 17␤-E 2 or 1␣,25(OH) 2 D 3 does not alone determine the extent of osteoclast-like cell formation. However, our results clearly show that, on the other side, the presence of the cytokine facilitates the action of 1␣,25(OH) 2 D 3 ; this must be inferred from the observation that 1␣,25(OH) 2 D 3 -dependent TRAP ϩ MNC formation could be partially reduced by addition of an anti-IL-6 monoclonal antibody to the bone marrow cell cultures (4) . It should be noted that, though the antibody concentration in these experiments was sufficient to virtually block any IL-6 bioactivity (see Materials and Methods), a substantial number of osteoclast-like cells could still be generated by 1␣,25(OH) 2 D 3 . This can be explained if one assumes that another cytokine, produced by marrow stromal cells, had a similar effect on osteoclastogenesis as IL-6. In fact, Girasole et al. (20) showed that IL-11 is produced in bone marrow cultures and, although it does not induce osteoclast formation alone, IL-11 significantly increased the number of osteoclasts induced by 1␣,25(OH) 2 D 3 in marrow cell cultures.
In any case, the blocking effect of an anti-IL-6 mAb on 1␣,25(OH) 2 D 3 -related osteoclast-like cell formation implies that the action of the vitamin D hormone, at least in part, depends on signal transduction via the IL-6 receptor. In this respect, it is of interest to note that expression of the signaltransducing protein gp130 (which is an integral part of the IL-6 receptor) in stromal bone marrow-derived cells is under control from 17␤-E 2 (21) . The lack of an additional inhibitory effect of a neutralizing anti-IL-6 mAb when 1␣,25(OH) 2 D 3 -related osteoclast-like cell formation is effectively suppressed by 17␤-E 2 (Fig. 4) strongly suggests that the estrogen, through inhibition of IL-6 signaling, also interferes with 1␣,25(OH) 2 D 3 induction of osteoclast-like cell formation. Although it seems logical to assume that IL-6 acts on osteoclast progenitors in mediating the differentiating action of 1␣,25(OH) 2 D 3 , Udagawa et al. (22) convincingly showed that in cocultures of mouse spleen and osteoblastic cells, osteoclast differentiation depends on the expression of IL-6 receptors on osteoblastic cells but not on osteoclast progenitors. From analogy, one could conclude that in our system, IL-6 signaling in marrow stromal cells, rather than in hematopoietic cells, plays a critical role in osteoclast-like cell formation.
Our results allow the conclusion that the antiresorptive effect of estrogens on bone turnover is not only the result of suppression of IL-6 production by marrow stromal or osteoblastic cells but, in consistence with data reported by Bellido et al. (21) , is also caused by an effective blockade of signal transduction on the IL-6 receptor pathway, which is clearly necessary for induction of osteoclastogenesis by 1␣,25(OH) 2 D 3 . This is consistent with the observation of Romas et al. (23) that positive effects of 1␣,25(OH) 2 D 3 on osteoclast-like cell formation in bone marrow cultures can be partially blocked by an anti-gp130 antibody. Our findings also shed some new light on the actual role of IL-6 in osteoclastogenesis, which seemingly involves sensitization of asyet-unidentified target cells to the action of the vitamin D hormone. The fact that 17␤-E 2 blocks IL-6-sensitive, 1␣,25(OH) 2 D 3 -dependent osteoclastogenesis at or downstream of IL-6 receptor activation suggests that the antiosteoporotic effect of estrogens is the result of their ability to induce a state of partial IL-6 resistance. Consequently, estrogen withdrawal would restore the ability of stromal or osteoblastic cells to respond to IL-6 and thereby to facilitate the formation of osteoclasts. It seems important to note that, even if estrogen deficiency would not or would only transiently cause an increase in IL-6 production in vivo (for discussion, see Refs. 19, 24, 25) , facilitation of L-6 and 1␣,25(OH) 2 D 3 interaction under this condition could still provide an explanation for the increase in bone loss observed in the menopause.
